Approved indications:

• Reduces the risk of major adverse cardiovascular events (cardiovascular death, heart attack, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.
• Used as an adjunct to diet and exercise to lower LDL cholesterol in adults with hypercholesterolemia, and in adults and children 10 years and older with heterozygous or homozygous familial hypercholesterolemia who need additional LDL lowering.

Off‑label or guideline‑driven uses:

• Often used in patients who are unable to tolerate adequate doses of statins or have contraindications to statins, to help achieve LDL‑cholesterol targets; this strategy is supported by guideline recommendations and outcome data, although statins remain first‑line therapy.
• Sometimes chosen specifically to help lower elevated lipoprotein(a) [Lp(a)], where it produces modest reductions; this use is supported by subgroup and mechanistic data but does not have a dedicated FDA indication.

Efficacy expectations:

• LDL cholesterol typically falls by about 50%–60% from baseline within 1–2 weeks of starting therapy and remains low with regular injections.
• In large cardiovascular outcome trials on top of statins, Repatha reduced major cardiovascular events by roughly 15%–25% over several years, depending on the population and exact composite endpoint.
• Compared with adding ezetimibe or further increasing statin dose, Repatha generally produces much greater LDL‑cholesterol reductions; its LDL‑lowering and event‑reduction effects are similar to other PCSK9 inhibitors, though it differs from some alternatives in dosing frequency (every 2 weeks or monthly).

Typical dosing by age and condition:

• Adults with hypercholesterolemia or at increased cardiovascular risk, and children 10 years and older with heterozygous familial hypercholesterolemia: 140 mg injected under the skin every 2 weeks or 420 mg once monthly.
• Adults and children 10 years and older with homozygous familial hypercholesterolemia: start with 420 mg once monthly; if the LDL‑cholesterol reduction is not sufficient after about 12 weeks, the dose may be increased to 420 mg every 2 weeks. Patients on lipid apheresis may start with 420 mg every 2 weeks given after the apheresis session.
• The 420‑mg dose can be delivered either by a single on‑body infusor with prefilled cartridge over about 5 minutes or by three consecutive 140‑mg injections within 30 minutes.

How to take the medicine:

• Inject Repatha under the skin of the abdomen (avoiding a 2‑inch area around the navel), thigh, or outer upper arm, rotating sites with each dose and avoiding skin that is red, bruised, hard, or scarred.
• Repatha may be given with or without food and at any time of day; try to inject on the same schedule (every 2 weeks or monthly) to maintain consistent effect.
• Keep devices refrigerated until use, then allow them to warm to room temperature for at least 30 minutes (prefilled syringe or autoinjector) or 45 minutes (on‑body infusor) before injection; do not use external heat and do not shake.
• Visually check that the solution is clear to slightly opalescent and colorless to pale yellow, without particles, before use; do not use if the solution appears abnormal.
• Patients and caregivers should receive training on preparation and injection technique and follow the Instructions for Use with each dose; some presentations contain latex in the needle cover, so people with latex allergy should receive a latex‑free version.

Missed‑dose guidance:

• If a dose is missed and it has been 7 days or less since the scheduled date, inject the missed dose as soon as possible and then continue with the original dosing schedule.
• If more than 7 days have passed:
  • For every‑2‑week dosing, skip the missed dose and inject the next dose on the usual date according to the original schedule.
  • For once‑monthly dosing, inject the missed dose as soon as possible and start a new monthly schedule counted from that date.

Overdose:

• Using more Repatha than prescribed may increase the chance of side effects; if too much is injected, contact a healthcare professional or poison control, and seek emergency care if severe symptoms occur.

Common side effects (usually mild to moderate):

• Upper respiratory symptoms such as runny nose, sore throat, nasopharyngitis, and flu‑like illness, as well as back pain and injection‑site redness, pain, or bruising, are the most frequently reported effects.
• Some people experience headache, mild gastrointestinal upset, or musculoskeletal pain (muscle or joint aches), but these are generally less common and tend to improve over time or with dose spacing.

Serious or rare adverse effects:

• Serious allergic or hypersensitivity reactions, including angioedema, can occur and require immediate medical attention (symptoms include trouble breathing or swallowing, hives, or swelling of the face, lips, tongue, or throat).
• Very low LDL‑cholesterol levels have not shown clear harm in clinical trials, but the long‑term impact of extremely low LDL levels is still being studied, so clinicians may monitor closely in patients with very low values.
• Neurocognitive events and new‑onset diabetes have been reported but were uncommon and occurred at rates similar to placebo in large studies.

Warnings and precautions:

• Contraindicated in anyone with a history of serious hypersensitivity to evolocumab or to any component of the product; some device needle covers contain dry natural rubber (a latex derivative), so latex‑sensitive patients should receive a latex‑free presentation.
• Pregnancy: human data are limited; as an IgG monoclonal antibody, Repatha can cross the placenta later in pregnancy, so it is generally reserved for situations where the cardiovascular benefits clearly outweigh potential risks.
• Breastfeeding: it is unknown if the drug passes into human milk; because oral absorption of such proteins by infants is likely low, many clinicians consider case‑by‑case use, especially avoiding exposure in newborn or preterm infants when possible.
• No dose adjustment is recommended for mild to moderate kidney or liver impairment, but data in severe dysfunction are limited, and such patients may need closer follow‑up.
• Safety and effectiveness have not been established in children younger than 10 years.

Overall safety profile:

• Repatha does not typically cause liver enzyme elevation or severe muscle injury, and routine liver‑function or muscle‑enzyme monitoring is not required solely because of this drug.
• Long‑term studies, including multi‑year extension trials, have shown a generally consistent and acceptable safety profile in high‑risk cardiovascular populations.

Reporting side effects and staying updated:

• Patients should promptly report any troublesome or persistent side effects, or any signs of allergic reaction, to their prescriber or pharmacist.
• Suspected serious adverse reactions can be reported to the FDA MedWatch program or to the manufacturer, and updated safety communications are available through FDA and manufacturer websites.

Drug and supplement interactions:

• Repatha is a monoclonal antibody broken down by general protein pathways rather than liver enzymes, and it is not known to have clinically important interactions with statins, ezetimibe, antiplatelet agents, anticoagulants, or most other common cardiovascular drugs.
• No specific interactions have been identified with over‑the‑counter medicines, vitamins, or herbal supplements, but patients should always provide a complete medication and supplement list to their clinician.
• Repatha is not known to interact with alcohol, though limiting alcohol intake is advisable for overall cardiovascular and metabolic health.

Food, vaccines, and procedures:

• Repatha can be taken without regard to meals and has no known interactions with particular foods.
• It is not an immunosuppressive medication, and there are no special restrictions on routine vaccinations; standard age‑ and condition‑based vaccine recommendations still apply.
• No specific precautions are required with imaging contrast dyes or most diagnostic procedures.

Precautions and conditions needing extra care:

• A history of serious hypersensitivity to evolocumab or to product components, including latex in some needle covers, is a contraindication.
• Pregnancy and breastfeeding require individualized risk‑benefit consideration, balancing cardiovascular risk against the limited data on fetal and infant exposure.
• Severe kidney or liver disease, or very frail patients, may warrant closer clinical follow‑up because trial data in these groups are more limited.

Monitoring needs:

• Clinicians typically check a lipid panel 4–8 weeks after starting Repatha or changing the dose, then periodically, to confirm LDL‑cholesterol response and guide long‑term therapy.
• Routine laboratory monitoring for liver enzymes, muscle enzymes, or drug levels is not required specifically for Repatha, although such tests may be needed for other medications or underlying conditions.

Q: How long does it take for Repatha to start lowering my cholesterol?
A: LDL cholesterol usually starts to fall within the first week and reaches most of its effect within about 1–2 weeks, as long as you keep taking your injections on schedule.

Q: Will I still need to take a statin if I am on Repatha?
A: Many people stay on a maximally tolerated statin (and often ezetimibe) with Repatha, because it is designed to add to other LDL‑lowering medicines, although it can be used alone in those who truly cannot tolerate statins.

Q: How long will I need to stay on Repatha?
A: Treatment is usually long term, since LDL cholesterol and cardiovascular risk tend to rise again if injections are stopped; your clinician will periodically reassess your risk, LDL levels, and side effects to decide whether to continue.

Q: Does Repatha cause weight gain or muscle pain like some statins?
A: Weight gain is not a known side effect, and while some people report muscle or joint aches, these are generally less frequent and less severe than with high‑dose statins.

Q: What should I do if I miss a Repatha dose?
A: If it has been 7 days or less since the missed dose, inject it as soon as you remember and then follow your original schedule; if more than 7 days have passed, follow the specific instructions for your every‑2‑week versus monthly regimen or ask your prescriber or pharmacist.

Q: Is Repatha safe to use with my other heart medications?
A: Repatha has not shown meaningful interactions with common heart drugs such as statins, beta‑blockers, ACE inhibitors, antiplatelets, or anticoagulants, so it is often used alongside them under medical supervision.

Storage:

• Keep Repatha in the refrigerator at 36°F–46°F (2°C–8°C) in the original carton to protect it from light; do not freeze or shake it.
• Before injecting, allow the prefilled syringe, autoinjector, or on‑body infusor to warm to room temperature for at least the time specified in the instructions (about 30 minutes for the syringe/autoinjector and 45 minutes for the on‑body infusor), without using external heat sources.
• If needed, a single device may be stored at room temperature 68°F–77°F (20°C–25°C) in the original carton for up to 30 days; once kept at room temperature, do not return it to the refrigerator and discard it if not used within 30 days or if exposed to extreme temperatures.
• Do not use the medicine if it has been frozen, or if the solution looks cloudy, discolored, or contains particles.

Disposal:

• Do not reuse needles, syringes, autoinjectors, or on‑body infusor cartridges, and do not throw loose sharps into household trash.
• Immediately place used devices into an FDA‑cleared sharps disposal container; if one is not available, use a heavy‑duty household container with a tight, puncture‑resistant lid and label it properly.
• Keep the sharps container out of the reach of children and pets, and when it is about three‑quarters full, follow local or state guidelines, or your pharmacist’s or health department’s advice, for safe disposal; do not recycle the sharps container.